Metabolic dysfunction-associated steatohepatitis (MASH) is a very hot area, with some therapies forecasts to sell in the billions and investors impatient for late-stage trial data. But working in this area is not a guarantee of success and there is a very real possibility that MASH specialist Inventiva S.A. will go bankrupt a few months short of completing enrolment in its Phase III trial.
Key Takeaways
- Inventiva has said it only has enough cash to last to the end of July.
On 5 July Inventiva said that its cash and equivalents, which stand at €19.7m ($21.3m), will run out by the...
